Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 2,225 Consensus Target Price from Brokerages

Hikma Pharmaceuticals PLC (LON:HIK) has received an average rating of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is GBX 2,250 ($28.73).

HIK has been the subject of a number of recent analyst reports. Berenberg Bank increased their target price on shares of Hikma Pharmaceuticals from GBX 2,000 ($25.54) to GBX 2,100 ($26.81) and gave the stock a “hold” rating in a research report on Monday. Barclays restated an “equal weight” rating and issued a GBX 2,000 ($25.54) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and set a GBX 2,750 ($35.11) price target on shares of Hikma Pharmaceuticals in a research report on Tuesday, June 18th.

Hikma Pharmaceuticals Price Performance

LON:HIK opened at GBX 2,004 ($25.59) on Wednesday. The company has a 50-day moving average of GBX 1,905 and a 200-day moving average of GBX 1,911.94. The company has a market capitalization of £4.45 billion, a price-to-earnings ratio of 2,968.66, a PEG ratio of 2.38 and a beta of 0.40. Hikma Pharmaceuticals has a 52 week low of GBX 1,711 ($21.85) and a 52 week high of GBX 2,216 ($28.29). The company has a debt-to-equity ratio of 55.48, a quick ratio of 1.27 and a current ratio of 1.66.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently disclosed a dividend, which will be paid on Friday, September 20th. Stockholders of record on Thursday, August 15th will be given a $0.32 dividend. This represents a dividend yield of 1.37%. The ex-dividend date of this dividend is Thursday, August 15th. Hikma Pharmaceuticals’s dividend payout ratio is presently 9,402.99%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.